Drug intelligence / Profile preview

BCD-057

Development stage: Phase 3
Lead developer: Biocad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

BCD-057 is an adalimumab biosimilar developed by Biocad. It is a fully human recombinant monoclonal IgG1 antibody that specifically targets tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, it prevents the activation of TNF receptors, which are responsible for inflammatory reactions associated with autoimmune diseases. BCD-057 has demonstrated equivalent efficacy, safety, pharmacokinetics, and immunogenicity to the innovator adalimumab (Humira) in clinical trials for moderate to severe plaque psoriasis.

Brand names: Dalibra
Other names: adalimumab-Biocadadalimumab biosimilar Biocad

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on BCD-057.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCD-057.

Explore the full profile